We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Read MoreHide Full Article
Repros Therapeutics Inc. (RPRX - Free Report) reported a loss of 18 cents per share in the second quarter of 2016, significantly narrower than the year-ago loss of 32 cents mainly due to lower research & development (R&D) expenses as well as lower payroll and benefits expenses and legal expenses. Second-quarter revenues (interest income) increased to $15,000 from $1,000 in the year-ago period.
R&D costs decreased 49.7% year over year to $3.2 million reflecting lower development expenses related to the enclomiphene product candidate, R&D payroll and benefits expenses and legal expenses. General and administrative expenses also decreased 22% year over year to $1.1 million.
Considering that Repros has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
Repros is currently working on gaining EU approval for enclomiphene (testosterone deficiency), where the company expects to submit a marketing application in Fall 2016. Meanwhile, in the U.S., a phase II double-blind, placebo controlled, proof of concept study (ZA-205) is being conducted in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. Six month data from this study is expected in the third quarter of 2016.
The company’s other pipeline candidate, Proellex, is in mid-stage development for the treatment of symptoms associated with uterine fibroids and endometriosis.
Repros is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector are Geron Corporation (GERN - Free Report) ), Incyte Corporation (INCY - Free Report) and Cambrex Corporation . All three carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Repros Therapeutics Inc. (RPRX - Free Report) reported a loss of 18 cents per share in the second quarter of 2016, significantly narrower than the year-ago loss of 32 cents mainly due to lower research & development (R&D) expenses as well as lower payroll and benefits expenses and legal expenses. Second-quarter revenues (interest income) increased to $15,000 from $1,000 in the year-ago period.
R&D costs decreased 49.7% year over year to $3.2 million reflecting lower development expenses related to the enclomiphene product candidate, R&D payroll and benefits expenses and legal expenses. General and administrative expenses also decreased 22% year over year to $1.1 million.
Considering that Repros has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
Repros is currently working on gaining EU approval for enclomiphene (testosterone deficiency), where the company expects to submit a marketing application in Fall 2016. Meanwhile, in the U.S., a phase II double-blind, placebo controlled, proof of concept study (ZA-205) is being conducted in obese secondary hypogonadal men to assess the impact of enclomiphene on metabolic parameters and quality of life under a diet and exercise regimen. Six month data from this study is expected in the third quarter of 2016.
The company’s other pipeline candidate, Proellex, is in mid-stage development for the treatment of symptoms associated with uterine fibroids and endometriosis.
REPROS THERAPEU Price
REPROS THERAPEU Price | REPROS THERAPEU Quote
Repros is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector are Geron Corporation (GERN - Free Report) ), Incyte Corporation (INCY - Free Report) and Cambrex Corporation . All three carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>